28 related articles for article (PubMed ID: 38483155)
1. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
Ren X; Zhang G; Li G; Wang Y
BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias.
Gomez-Lumbreras A; Mercadal Vilchez S; Villa-Zapata L; Malone DC; Couriel DR
Leuk Lymphoma; 2023 Dec; 64(13):2071-2080. PubMed ID: 37708442
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
4. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
5. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
[TBL] [Abstract][Full Text] [Related]
6. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.
Elsallab M; Ellithi M; Lunning MA; D'Angelo C; Ma J; Perales MA; Frigault M; Maus MV
Blood; 2024 May; 143(20):2099-2105. PubMed ID: 38483155
[TBL] [Abstract][Full Text] [Related]
7. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS).
Yu RJ; Krantz MS; Phillips EJ; Stone CA
J Allergy Clin Immunol Pract; 2021 Feb; 9(2):819-829.e2. PubMed ID: 32992044
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
9. Current status of CAR-T cell therapy for pediatric hematologic malignancies.
Hiramatsu H
Int J Clin Oncol; 2023 Jun; 28(6):729-735. PubMed ID: 37154980
[TBL] [Abstract][Full Text] [Related]
10. Medication overdose data analysis: a review of medication error reports in the FDA adverse event reporting system (FAERS).
Ni J; Tang X; Chen L
BMC Pharmacol Toxicol; 2023 Aug; 24(1):41. PubMed ID: 37542326
[TBL] [Abstract][Full Text] [Related]
11. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).
Sabol RA; Noxon V; Sartor O; Berger JR; Qureshi Z; Raisch DW; Norris LB; Yarnold PR; Georgantopoulos P; Hrushesky WJ; Bobolts L; Ray P; Lebby A; Kane RC; Bennett CL
Cancer Med; 2017 Jul; 6(7):1541-1551. PubMed ID: 28635055
[TBL] [Abstract][Full Text] [Related]
12. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
